Category: elsevier

Univ.: No misconduct, but “poor research practice” in mgt prof’s work now subject to 7 retractions

fred-walumbwa
Fred Walumbwa

The Leadership Quarterly has retracted a trio of papers by Frederick Walumbwa, an “ethical leadership” guru at Florida International University, whose work has come under scrutiny for flawed methodology. And another journal  has pulled one of his articles for similar reasons. That brings his count – as far as we can tell — to seven retractions and a mega-correction.

Meanwhile, Arizona State University, Walumbwa’s former employer, has found

that the preponderance of evidence does not support the charge of research misconduct by Dr. Walumbwa…

but that he engaged in “poor research practice.”

The bottom line, according to the Leadership Quarterly, which first announced problems with the articles in February:

Continue reading Univ.: No misconduct, but “poor research practice” in mgt prof’s work now subject to 7 retractions

Lancet journal puts ICU paper on watch after authors acknowledge potentially fatal flaw

lancetrmLancet Respiratory Medicine has issued an expression of concern for a meta-analysis on tracheostomy in the intensive care unit that they published earlier this year.

The paper, “Effect of early versus late or no tracheostomy on mortality of critically ill patients receiving mechanical ventilation: a systematic review and meta-analysis“, came from a group at Harvard, Weill Cornell and the University of Athens. The authors purported to find that: Continue reading Lancet journal puts ICU paper on watch after authors acknowledge potentially fatal flaw

“I kind of like that about science:” Harvard diabetes breakthrough muddied by two new papers

douglas_melton
Doug Melton

Harvard stem cell researcher Doug Melton got a lot of press last year for research on a hormone he named betatrophin, after its supposed ability to increase production of beta cells, which regulate insulin.

Now, the conclusions from that paper, which has been cited 59 times, according to Thomson Scientific’s Web of Knowledge, have been called into question by research from an independent group, as well as follow-up work from the original team.

The interest was driven by the hormone’s potential as a new treatment for diabetes. In 2013, Melton told the Harvard Gazette that betatrophin could be in clinical trials within three to five years. Here’s Kerry Grens in The Scientist: Continue reading “I kind of like that about science:” Harvard diabetes breakthrough muddied by two new papers

Will journal finally retract fraudulent paper 10 months after an official request?

ChemosphereElsevier journal Chemosphere may finally retract a paper it learned contained fabricated data in January when a member of the author’s institution requested the paper be retracted.

The paper has been cited at least once since the lies came to light, as we reported earlier this month.

The journal contacted the relevant parties on October 29 with the following email about “Degradation of 2,4-dinitroanisole (DNAN) by metabolic cooperative activity of Pseudomonas sp. strain FK357andRhodococcus imtechensis strain RKJ300,” although no notice has been posted: Continue reading Will journal finally retract fraudulent paper 10 months after an official request?

Structure error sinks NIH-MIT-SNU peptide paper

CHBIOL_21_9.c1.inddA mistake in structure identification has sunk a paper by researchers at the NIH, MIT, and Seoul National University in the Cell Press journal Chemistry and Biology.

Here’s the notice for “Peptide-Based Inhibitors of Plk1 Polo-box Domain Containing Mono-anionic Phosphothreonine Esters and Their Pivaloyloxymethyl Prodrugs”: Continue reading Structure error sinks NIH-MIT-SNU peptide paper

“Our real intention was to emphasize, not plagiarize”

joms.13692132This one’s not a retraction, but rather a back and forth of letters to the editor concerning accusations of plagiarism.

Dentists Bryan and Paul Jacobs, a father and son team, wrote a paper describing a novel surgical technique in March 2013. In October 2013, several Croatian dentists published their own paper using the technique.

A year later, the story has gotten a little more interesting. The November issue of the Journal of Oral and Mixillofacial Surgery, which published the second article, has two letters. One, from the Jacobses, accuses the Croatian authors of plagiarism. The second is a response from author Dragana Gabrić Pandurić, claiming “our real intention was to emphasize, not plagiarize, their work.”

Here’s the letter from Bryan and Paul Jacobs (paywalled): Continue reading “Our real intention was to emphasize, not plagiarize”

Journal expresses concerns over “possible data irregularities” in paper from Army medical center docs

JAADThe Journal of the American Academy of Dermatology has issued an expression of concern about a 2012 article reporting the experience of military burn unit treating a rare ailment called toxic epidermal necrolysis.

According to the notice, which is behind a paywall (for shame!), the paper appears to have overstated the number of cases the hospital itself has treated of the life-threatening condition: Continue reading Journal expresses concerns over “possible data irregularities” in paper from Army medical center docs

U. Illinois chancellor earns mega-correction for duplicate publication

Phyllis Wise, from University of Illinois
Phyllis Wise, via University of Illinois

Phyllis Wise, the chancellor of the University of Illinois and an obstetrics researcher, has called for a massive correction of a 2006 paper in Neuroscience for work she appears to have tried to pass off as having been previously unpublished — but which wasn’t.

The article, “Estrogen therapy: Does it help or hurt the adult and aging brain? Insights derived from animal models,” has been cited 47 times, according to Thomson Scientific’s Web of Knowledge.

And it had caught also the attention of readers on PubPeer, who noted that: Continue reading U. Illinois chancellor earns mega-correction for duplicate publication

Oops: Elsevier journal publishes paper citing paper it promised to retract two months ago

elsevierJournal publishers can be agonizingly slow when it comes to officially retracting a paper.

Here’s a prime example of the consequences of that bureaucratic foot-dragging: Ten months after being told that Fazlurrahman Khan had fabricated his data, and two months after announcing two of Khan’s papers would be retracted from two of its journals, Elsevier still has not retracted either paper.

Worse, at least one of the papers, “Degradation of 2,4-dinitroanisole (DNAN) by metabolic cooperative activity of Pseudomonas sp. strain FK357 and Rhodococcus imtechensis strain RKJ300,” in the journal Chemosphere, has been cited since the announcement was made. In fact, the paper was published in Journal of Hazardous Materials, the Elsevier journal that is dragging its feet retracting another of Khan’s papers, “Aerobic degradation of 4-nitroaniline (4-NA) via novel degradation intermediates by Rhodococcus sp. strain FK48.”

Jim Spain, in whose lab Khan worked at Georgia Tech, reached out to us to express his concerns with this timeline: Continue reading Oops: Elsevier journal publishes paper citing paper it promised to retract two months ago

Double dipping on trial data topples 17-year-old macular degeneration article

redjournalThe authors of a 1997 paper on macular degeneration have lost the article after readers noticed uncanny similarities with a 1996 publication from several of the same authors.

The retracted article, “Radiation therapy for macular degeneration: Technical considerations and preliminary results,” appeared in the International Journal of Radiation Oncology*Biology*Physics — otherwise known as the “Red Journal.” The first author, Luther W. Brady, is a leading U.S. oncologist.

According to the retraction notice: Continue reading Double dipping on trial data topples 17-year-old macular degeneration article